← Back to Search

Behavioural Intervention

AAT + tDCS for Smoking Cessation

N/A
Recruiting
Led By Cynthia Conklin, PhD
Research Sponsored by Cynthia Conklin
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Between the ages of 26 & 55
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to approximately 6 weeks
Awards & highlights

Study Summary

This trial will test a new treatment for smokers that includes exposure to smoking-related stimuli combined with brain stimulation in an attempt to reduce smoking and increase the intent to quit.

Who is the study for?
This trial is for smokers aged 26-55 who smoke more than 7 cigarettes daily, have a high interest in quitting within the next six months, and can commit to attending ten sessions over three weeks plus two phone follow-ups. Participants must not have epilepsy, substance dependence (except nicotine), brain devices, significant head trauma history, severe allergies like latex or uncontrolled diabetes.Check my eligibility
What is being tested?
The study tests a new treatment combining an Approach/Avoidance Task (AAT) with Transcranial Direct Current Stimulation (tDCS) targeting the brain's prefrontal cortex during exposure to smoking cues. The aim is to reduce cravings and smoking behavior while boosting confidence and intent to quit.See study design
What are the potential side effects?
Potential side effects of tDCS may include discomfort at the electrode site on the scalp, itching or tingling sensations during stimulation, fatigue, headache or nausea. However, these are generally mild and temporary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 26 and 55 years old.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to approximately 6-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to approximately 6-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Mean Change from baseline in 4-item Questionnaire on Smoking Urges craving score during cue reactivity to personal cues
Mean Change from baseline in number cigarettes smoked daily
Mean Change from baseline in rating score for 5-item Intent to Quit Questionnaire
+1 more
Secondary outcome measures
Age as a moderator of cue-induced craving
Age as a moderator of of cigarettes smoked per day
Baseline measure of Fagerstrom Test of Nicotine Dependence (FTND) as moderator of cigarettes per day
+3 more

Trial Design

4Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: AAT + tDCSExperimental Treatment2 Interventions
Approach Avoidance Task + Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
Group II: AC + tDCSActive Control2 Interventions
Active Control Task with Transcranial Direct Current Stimulation targeting the dorsolateral prefrontal cortex
Group III: AAT + sham tDCSPlacebo Group2 Interventions
Approach Avoidance Task with Sham Transcranial Direct Current Stimulation.
Group IV: AC + sham tDCSPlacebo Group2 Interventions
Active Control Task with sham Transcranial Direct Current Stimulation
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation
2014
Completed Phase 3
~1100

Find a Location

Who is running the clinical trial?

Cynthia ConklinLead Sponsor
1 Previous Clinical Trials
121 Total Patients Enrolled
National Institute on Drug Abuse (NIDA)NIH
2,468 Previous Clinical Trials
2,619,269 Total Patients Enrolled
67 Trials studying Smoking
22,620 Patients Enrolled for Smoking
Cynthia Conklin, PhDPrincipal InvestigatorUniversity of Pittsburgh
2 Previous Clinical Trials
160 Total Patients Enrolled

Media Library

Approach/Avoidance Task (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05426460 — N/A
Smoking Research Study Groups: AAT + tDCS, AAT + sham tDCS, AC + tDCS, AC + sham tDCS
Smoking Clinical Trial 2023: Approach/Avoidance Task Highlights & Side Effects. Trial Name: NCT05426460 — N/A
Approach/Avoidance Task (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05426460 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What criteria must a person meet in order to qualify for this research project?

"Those hoping to be included in this clinical trial must have a history of smoking cigarettes and fall between the ages of 26-55. Currently, there is space for 80 participants."

Answered by AI

What is the main purpose of this clinical trial?

"This trial will analyse the mean change from baseline in regards to smoking urges cravings over a 6-week period. Additionally, it will gauge sex and age as moderators of cue-induced craving, alongside evaluating the correlation between age and cigarettes smoked per day."

Answered by AI

Is this study recruiting participants younger than 40 years old?

"The requirements for participation in this trial state that volunteers must be between the ages of 26 and 55. Those under 18 or over 65 are advised to look into 2 separate studies tailored for their respective age brackets, with 43 such trials available."

Answered by AI

How many participants have joined this clinical experiment?

"Affirmative. Clinicaltrials.gov reveals that this clinical study, which was first posted on April 29th 2022 is recruiting patients in earnest. To complete the trial 80 more participants need to be sourced from one specific location."

Answered by AI

Is enrollment available for this experiment at the present moment?

"Current information on clinicaltrials.gov reveals that this medical trial is still open for recruitment. It was first posted to the site on April 29th 2022 and recently updated on June 15th 2022."

Answered by AI

Who else is applying?

What state do they live in?
Michigan
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
3+
What site did they apply to?
University of Pittsburgh
Recent research and studies
clinicaltrials.govStudy
AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior
Cynthia Conklin 2022. "AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05426460.
~27 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top